News

ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with in vitro and in vivo model systems.

“ATCC is committed to supporting this global health initiative by providing the novel scientific research and development solutions needed to address these high-morbidity and mortality infectious disease outcomes,” said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. “Through our new partnership with DTRA, we now have the opportunity to focus on the development of novel machine learning (ML) and artificial intelligence (AI) models for countermeasure identification that may lead to better vaccine and therapeutic solutions, which are needed to save lives.”

Specifically, ATCC’s role will be to employ multiple experimental platforms to define new targets for therapeutics, evaluate novel and/or FDA-approved candidates for antiviral and anti-inflammatory activities, and define relevant infection-associated biomarkers. This information will be used to develop AI models of disease and therapeutic effectiveness. ATCC will also employ ML/AI strategies to integrate the cellular response datasets and identify broad-spectrum therapeutic candidates to combat various pathogens. The promising candidates will be tested with novel organoid models (organ-on-a-chip) in an iterative and sequential transition from in vitro to in vivo platforms. This is seen as a critical step in the one-drug-many-bugs approach to antiviral product development and will be an important contribution to improving our country’s pandemic preparedness resiliency in dealing with the current and future challenges.

“ATCC is proud to provide its expertise in global health and biodefense to support federal infectious disease research and development programs and the DoD with this new grant from DTRA,” said Joseph Leonelli, Ph.D., senior vice president of ATCC Federal Solutions (AFS).

Dr. Aarthi Narayanan, director of Translational Research and Technology Transfer at ATCC, will lead this research. She brings her deep expertise in virology and preclinical product development to the AFS team and oversees translating cutting-edge research into technologies and products that will continue to improve global health and biodefense.

Read more here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by